During the last session, Phio Pharmaceuticals Corp (NASDAQ:PHIO)’s traded shares were 0.33 million, with the beta value of the company hitting 0.82. At the end of the trading day, the stock’s price was $1.76, reflecting an intraday loss of -2.22% or -$0.04. The 52-week high for the PHIO share is $9.79, that puts it down -456.25 from that peak though still a striking 44.89% gain since the share price plummeted to a 52-week low of $0.97. The company’s market capitalization is $8.41M, and the average trade volume was 3.13 million shares over the past three months.

Phio Pharmaceuticals Corp (NASDAQ:PHIO) trade information

Phio Pharmaceuticals Corp (PHIO) registered a -2.22% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -2.22% in intraday trading to $1.76, hitting a weekly high. The stock’s 5-day price performance is -10.20%, and it has moved by 14.29% in 30 days. Based on these gigs, the overall price performance for the year is -76.62%.

An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 66.30%. While earnings are projected to return 147.36% in 2025.

PHIO Dividends

Phio Pharmaceuticals Corp is due to release its next quarterly earnings in June. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.

Also, the Mutual Funds coming in first place with the largest holdings of Phio Pharmaceuticals Corp (PHIO) shares are Fidelity Concord Street Trust-Fidelity Extended Market Index Fund and VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund . Data provided on Mar 31, 2025 indicates that Fidelity Concord Street Trust-Fidelity Extended Market Index Fund owns about 28.43 shares. This amounts to just over 0.59 percent of the company’s overall shares, with a $50033.0 market value. The same data shows that the other fund manager holds slightly less at 2.71, or about 0.06% of the stock, which is worth about $4764.0.